Amphastar Pharmaceuticals (AMPH) Profit After Tax (2013 - 2026)

Amphastar Pharmaceuticals' Profit After Tax history runs 14 years deep, the most recent figure standing at $6.4 million for Q1 2026.

• On a quarterly basis, Profit After Tax fell 74.61% year-over-year to $6.4 million in Q1 2026; TTM through Mar 2026 was $79.2 million, a 43.83% decrease from a year earlier, with the FY2025 full-year figure at $98.1 million, down 38.51% from the prior year.
• Profit After Tax retreated to $6.4 million in Q1 2026 per AMPH's latest filing, from $24.4 million in the prior quarter.
• Across five years, Profit After Tax topped out at $49.6 million in Q3 2023 and bottomed at $6.4 million in Q1 2026.
• The 5-year median for Profit After Tax is $26.1 million (2023), against an average of $29.2 million.
• Across the five-year window, Profit After Tax jumped 381.11% in 2022 and slumped 74.61% in 2026, its largest moves.
• Year by year, Profit After Tax stood at $35.1 million in 2022, then grew by 8.71% to $38.1 million in 2023, then declined by 1.98% to $37.4 million in 2024, then sank by 34.67% to $24.4 million in 2025, then sank by 73.72% to $6.4 million in 2026.
• Per Business Quant, the three latest AMPH Profit After Tax figures stand at $6.4 million (Q1 2026), $24.4 million (Q4 2025), and $17.3 million (Q3 2025).